bsm-51720M [Primary Antibody]
RAB5B Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: RAB5B

Clonality: Monoclonal

Isotype: Not determined

Entrez Gene: 5869

Swiss Prot: P61020

Source: Recombinant human RAB5B.

Purification: Purified by Protein G.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Rab5b is a member of the Rab family of small (monomeric) G proteins. Like other small G proteins, Rab5b switches between an inactive, GDP-form and an active, GTP-bound form. GDP/GTP exchange factors (GEFs) catalyse the conversion from the GDP-bound form to the GTP-bound form, while GTPase-activating proteins (GAPs) catalyse GTP hydrolysis to GDP. Rab5b is involved in endocytosis and recycling of cell surface molecules. It interacts with RIN2 and RIN3, which regulate its function, possibly by acting as GEFs. Knockdown of Rab5b abolished group I metabotropic glutamate receptor (mGluR)-mediated neuroprotection. Furthermore, Rab5b interacts with LRRK2, the defective gene at the PARK8 locus that results in Parkinson's disease. Roles for Rab5b in neurodegenerative disease, neuroprotection, and synaptic plasticity have been suggested.

Size: 100ul

Concentration: 0.5ug/ul

Applications: WB=1:500-2000，

Predicted Molecular Weight: 24


Predicted Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: A431 cell lysates probed with RAB5B Monoclonal Antibody, Unconjugated (bsm-51720M) at 1:2000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


Lane 1: Hela cell lysates; Lane 2: HepG2 cell lysates; Lane 3: Jurkat cell lysates; Lane 4: NIH/3T3 cell lysates probed with RAB5B Monoclonal Antibody, Unconjugated (bsm-51720M) at 1:2000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.